[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontal-pocket\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontal-pocket":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,44,76,98,116,141,165,189,208,228,249,271,294,319,346,372],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100539890","hyaluronic-acid-and-polynucleotides-for-supra-bony-defects-100539890",false,"NCT06309719","Hyaluronic Acid and Polynucleotides for Supra-bony Defects","Characterizing the Healing of Periodontal Supra-bony Defects Treated With Hyaluronic Acid and Polynucleotides","Inclusion Criteria:\n\n* Systemically healthy males and females ≥18 years old\n* Stage III or IV periodontitis (Papapanou, Sanz et al. 2018)\n* Presence of supra-bony periodontal defects (i.e., defects where the base of the pocket is located coronal to the alveolar crest and characterized by a predominantly horizontal pattern of tissue destruction) confirmed clinically and radiographically at a minimum of two and a maximum of four adjacent teeth and with a probing pocket depth (PPD) \\> 5 mm, following non-surgical periodontal therapy (NSPT). If \\>4 adjacent teeth exhibited the above clinical and radiographic conditions, the four adjacent teeth showing the greatest overall loss of periodontal attachment were included. Wisdom teeth and second molars will not be considered for the study.\n\nIf defect presents with an intrabony component, this should be ≤2 mm.\n\n* Non-surgical periodontal treatment (step 1 and 2) completed within the previous 4 months\n* Full-mouth bleeding score (FMBS) and full-mouth plaque score (FMPS) ≤20%\n\nExclusion Criteria:\n\n* Teeth with degree III mobility\n* Multi-rooted teeth with grade ≥2 furcation involvement\n* Heavy smokers (≥10 cigarettes a day)\n* Untreated caries or endodontic lesions or abscesses on the teeth involved in the surgery\n* Previous periodontal surgery in the area selected for the study\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures (e.g., mitral valve prolapse, artificial heart)\n* Antibiotic or anticoagulant therapy during the month preceding the baseline exam.\n* History of alcohol or drug abuse\n* Medical history that includes uncontrolled diabetes or hepatic or renal diseases, or other serious medical conditions that can have a negative impact on the periodontal condition\n* In treatment with medications that can severely affect bone metabolism and blood clot formation (e.g., anticoagulants, long-term corticosteroids, bisphosphonates, immunosuppressants)\n* Self-reported pregnancy or lactation.","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel.",[26,27,28,29,30],"Periodontal Diseases","Wound Heal","Periodontal Inflammation","Periodontal Pocket","Periodontal Attachment Loss","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2024-10-21",{"date":39,"type":20},"2026-12",{"name":41,"class":42},"Queen Mary University of London","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100629249","periodontal-dressings-in-non-surgical-therapy-100629249","NCT07472218","Periodontal Dressings in Non-Surgical Therapy","Comparison of the Effectiveness of Two Different Periodontal Wound Dressings in Non-Surgical Periodontal Therapy","Inclusion Criteria:\n\n1. Systemically healthy volunteers aged 18-45 years.\n2. Diagnosis of Periodontitis (Stage 3, Grade A).\n3. Presence of at least 20 permanent teeth.\n4. Capacity to understand the study protocol and provide informed consent.\n\nExclusion Criteria:\n\n1. Systemic diseases (e.g., Diabetes, Chronic Renal Failure, Cancer, Connective Tissue Disorders).\n2. Pregnancy or breastfeeding.\n3. Smoking (\\>10 cigarettes\u002Fday).\n4. Antibiotic use within the last 3 months or periodontal treatment within the last year.\n5. Presence of orthodontic appliances, removable prostheses, or extensive interproximal caries.","60 Years",{"count":53,"type":20},25,[23],"This study aims to evaluate and compare the efficacy of two different eugenol-free periodontal dressing materials-Ora-Aid (a hydrophilic polymer) and Coe-Pak (a zinc oxide-based paste)-following non-surgical periodontal treatment (scaling and root planing, SRP) in patients with Stage 3, Grade A periodontitis. The study utilizes a split-mouth design to analyze clinical periodontal parameters, patient comfort, and microbiological changes over a 3-month period.",[57,58,29],"Periodontitis","Periodontitis (Stage 3)",[60,61,62,63,64,65],"periodontitis","Non-surgical periodontal therapy","Periodontal dressing","Ora-Aid","Coe-Pak","total bacterial load","NOT_YET_RECRUITING","2026-03-13",{"date":69,"type":35},"2026-03-16",{"date":71,"type":20},"2026-04-01",{"date":73,"type":20},"2026-10-01",{"name":75,"class":42},"Saglik Bilimleri Universitesi",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100480249","periodontal-granulation-tissue-preservation-in-surgical-periodontitis-treatment-100480249","NCT05533528","Periodontal Granulation Tissue Preservation in Surgical Periodontitis Treatment","Periodontal Granulation Tissue Preservation in Surgical Periodontal Disease Treatment. A Randomized Clinical Trial","Inclusion Criteria:\n\n* Stage III or IV periodontitis, including all grades.\n* Unresolved deep pockets (probing pocket depth \\[PPD\\] \\>5 mm + BoP) 4 to 6 weeks after non-surgical treatment.\n* Interproximal plaque index \\\u003C35% maintained during periodontal treatment and maintenance.\n* Adherence to periodontal maintenance appointments.\n\nExclusion Criteria:\n\n* Systemic disease contraindicating periodontal surgery.\n* Teeth with incorrect endodontic treatment or restoration.\n* Stage I or II periodontitis.",{"count":53,"type":20},[23],"The objective of this study will be to evaluate a new protocol for the surgical treatment of periodontal disease with two novelties: to make a single incision in the midline of the interproximal area to respect the vascular supply and preserve the granulation tissue with regenerative potential.\n\nThe investigators will carry out a controlled and randomized clinical trial with a control group (n=25; modified Kirkland flap) and a test group (n=25; experimental surgical protocol: incision in the mid-interproximal area of the papilla and preservation of the granulation tissue).\n\nClinical parameters will be taken at the time of surgery and 12 months follow-up: bleeding on probing (BoP), clinical attachment level (CAL), residual probing depth (rPD),Probing pocket depth reduction (PPDr), recession (REC), interproximal gingival recession (iGR), width of keratinized gingiva (KT), gain of supra-alveolar clinical attachment (SUPRA-AG), early wound healing index (EHI).",[29,26,87],"Periodontal Bone Loss","2026-02-16",{"date":90,"type":35},"2026-02-19",{"date":92,"type":35},"2022-05-03",{"date":94,"type":20},"2027-02-01",{"name":96,"class":42},"Universidad de Murcia",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":115,"locationsCount":97},"100362312","nipsa-versus-marginal-approach-by-palatal-incision-and-mist-in-periodontal-regeneration-100362312","NCT03997552","NIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration","Non-Incised Papillae Surgical Approach (NIPSA) Versus Marginal Approach by Palatal Incision and Minimally Invasive Surgical Technique (MIST) in Periodontal Regeneration: a Ramdomized Clinical Trial","Inclusion Criteria:\n\n* patients diagnosed with periodontitis.\n* plaque index and bleeding index of \\\u003C 30%.\n* periodontal lesions with pocket probing depth \\> 5 mm.\n* intrabony defect \\> 3 mm.\n* intrabony defect configuration including a 1 and\u002For 2-wall component, always involving the buccal wall.\n\nExclusion Criteria:\n\n* patients with systemic diseases that contraindicated treatment.\n* third molars.\n* teeth with incorrect endodontic or restorative treatment.",{"count":106,"type":20},60,[23],"Three techniques for periodontal reconstruction will be compared, in which marginal access versus apical access will be carried out.",[57,26,29],{"date":111,"type":35},"2026-02-17",{"date":113,"type":35},"2019-09-06",{"date":94,"type":20},{"name":96,"class":42},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":43},"100556233","hyaluronic-acid-and-octenidine-gel-as-an-adjunct-to-non-surgical-periodontal-treatment-100556233","NCT06522438","Hyaluronic Acid and Octenidine Gel as an Adjunct to Non-surgical Periodontal Treatment","Early Healing Dynamics and Microbial Changes Following the Use of a Novel Thermosensitive Gel With Hyaluronic Acid and Octenidine as an Adjunct to Non-surgical Periodontal Treatment","Inclusion Criteria:\n\n* Male or female aged 18 and above\n* Engaged patients presenting with a Full Mouth Plaque Score (FMPS) of ≤ 20% within the 6 weeks prior to enrolment, or exhibiting a ≥ 50% reduction in plaque score from the initial screening visit.\n* Periodontitis stage III\u002FIV (grades A to C) with at least one site per quadrant with PPD ≥5mm, bleeding on probing and attachment loss ≥5mm\n* Willing to sign informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Know hypersensitivity and\u002For allergy to any of the product's component (as per user leaflet)\n* Self-reported pregnancy or lactation\n* Smoking (current or in past 5 years), including e-cigarettes\u002Fvaping\n* Medical history including diabetes mellitus or other serious medical\u002F psychiatric conditions or transmittable diseases that according to the investigator may increase the risk associated with study participation\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures or\u002Fand systemic antibiotic therapy during the 3 months preceding the baseline evaluation\n* In chronic treatment with anti-inflammatory (including corticosteroids), anticoagulants\u002Fantiplatelets (including aspirin), immunosuppressants or other medication that can severely impact wound healing\n* History of alcohol or drug abuse\n* Subgingival professional mechanical plaque removal (excluding not-extensive subgingival debridement as judged by the examining clinician) and\u002For surgical periodontal treatment within the last 12 months\n* Other severe acute or chronic medical or psychiatric condition or psychological disorder, including limited mental capacity or language skills such that study information could not be understood, informed consent could not be obtained, or simple instructions could not be followed, or any additional conditions which, in the judgement of the investigator, would make the subject inappropriate for entry into this trial",{"count":124,"type":20},26,[23],"This parallel-group, pilot study will test the hypothesis that the adjunctive use of a thermosensitive gel containing Hyaluronic Acid (HA) and Octenidine to non-surgical periodontal treatment (NSPT) will be able to modulate the early wound healing events. This will be assessed through the expression of specific gingival crevicular fluid markers, as well as by changes in gingival blood flow (assessed by laser speckle contrast imaging), bacterial load, soft tissues contour, clinical parameters and patient-reported outcomes.\n\nThe study will involve up to 26 patients and will take place at the Centre for Oral Clinical Research (COCR), at the Institute of Dentistry, Faculty of Medicine and Dentistry, Queen Mary University of London under The Royal London Dental Hospital, Barts Health NHS Trust. Patients will be randomised to receive either NSPT alone or NSPT+ HA and Octenidine gel, and will be followed up to 3 months after treatment.\n\nThe study will consist of 7- 8 visits.",[57,27,29,28,30],[129,130,131,132],"Hyaluronic Acid","Octenidine","Biomarkers","Non-surgical periodontal treatment","2026-02-03",{"date":135,"type":35},"2026-02-05",{"date":137,"type":35},"2025-06-03",{"date":139,"type":20},"2027-12-31",{"name":41,"class":42},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":4},"100608246","occlusal-load-distribution-and-periodontal-status-100608246","NCT07199062","Occlusal Load Distribution and Periodontal Status","Correlation Between Occlusal Load Distribution and Periodontal Status: A Cohort Study","Perio-Occlusio","Inclusion Criteria:\n\n* Adults (≥18 years).\n* Presence of natural dentition, fixed prostheses, or implant-supported fixed prostheses.\n* Ability to undergo radiological (OPT) and periodontal examinations.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients wearing removable prostheses.\n* Severe systemic conditions contraindicating dental treatment.\n* Inability to provide informed consent.",true,"75 Years",{"count":152,"type":20},50,"OBSERVATIONAL","Occlusal forces are unevenly distributed among teeth during mastication, potentially predisposing certain teeth to higher functional loads. Teeth subjected to increased occlusal loading may be at greater risk of periodontal breakdown, especially in patients with pre-existing periodontal disease.\n\nTechnological advances, such as mandibular movement recording systems, allow for precise assessment of occlusal contacts and load distribution. However, the relationship between occlusal loading patterns and periodontal status remains insufficiently investigated.\n\nThis study aims to evaluate whether teeth exposed to higher masticatory loads show an association with periodontal disease severity.",[26,29,57,156],"Periimplantitis","2025-09-21",{"date":159,"type":35},"2025-09-30",{"date":161,"type":20},"2025-10-01",{"date":71,"type":20},{"name":164,"class":42},"University of Bari Aldo Moro",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":149,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":97},"100591457","ozonized-olive-oil-in-the-treatment-of-periodontal-pockets-100591457","NCT06980675","Ozonized Olive Oil in the Treatment of Periodontal Pockets","Clinical and Microbiological Study on Local Application of an Ozonated Olive Oil Gel in the Periodontal Pockets: a Randomized Double-blind Trial.","Inclusion Criteria:\n\n* Patients with stage II, III, or IV periodontitis according to the new 2017 World Workshop periodontal classification\n* Patients of either sex and older than 18 years of age\n* Probing Pocket Depth (PPD) greater than or equal to 4 mm at 3 sites\n* Patients who have signed consent to the study\n* Collaborating patients\n\nExclusion Criteria:\n\n* age \\\u003C 18 years and\u002For inability to provide written informed consent;\n* absence of family or social welfare support;\n* non-drug-induced gingival hypertrophy,\n* severe smokers (more than 20 cigarettes per day),\n* consumers of high levels of alcohol,\n* patients on corticosteroid treatment,\n* diabetic patient,\n* immunodepressive therapies,\n* chemotherapies,\n* radiotherapies,\n* pregnancy states;\n* lack of collaboration for ongoing postoperative reevaluations.",{"count":173,"type":20},20,[23],"A randomized controlled clinical trial was conducted on 16 patients (8 males and 8 women) who were diagnosed chronic periodontitis. All the patients has been divided by randomization in two groups: control group treated with placebo gel and experimental group treated with gel based on ozonated EVO olive oil.\n\nBoth group after the evaluation of inclusion and exclusion criteria during the first visit, were subjected to hygiene treatment of removal tartar deposit, considered as standard of therapy for periodontitis.\n\nAfter 15 days the hygiene treatment, patients were been randomized in two groups following the flow chart (t0) starting with: periodontal probing, microbiological samples and the first administration of gel. Next week (t1), has been collected the compliance and did the second administration of gel; the procedures will be the same also for another week (t2), until the last week (t3) when has been registered the second periodontal probing and did the second microbiological samples.\n\nData were collected to software Microsoft Excel and all the data analysis were conducted on this software to highlight significant differences between both groups. As the primary outcome was continuous variable and assuming normal distribution bilateral parametric test T-student was performed. An alpha error of 5% was considered, Beta error was not calculated as this was a pilot study.",[29],[178,29,179],"Ozonated Olive Oil","Periodontal Disease","2025-05-16",{"date":182,"type":35},"2025-05-20",{"date":184,"type":35},"2021-10-25",{"date":186,"type":20},"2025-05",{"name":188,"class":42},"University of Bari",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":97},"100446077","comparing-different-timings-for-periodontal-re-evaluation-after-non-surgical-periodontal-therapy-nspt-100446077","NCT05088746","Comparing Different Timings for Periodontal Re-evaluation After Non-surgical Periodontal Therapy (NSPT)","Inclusion Criteria:\n\n* Systemically healthy males and females ≥18 years old\n* Willingness to read and sign a copy of the Informed Consent Form after reading the Patient Information Sheet, and after the nature of the study has been fully explained\n* Clinical evidence of periodontitis, defined as the presence of interdental clinical attachment loss detectable at ≥2 non-adjacent teeth or buccal or oral clinical attachment loss ≥3mm with pocketing \\>3 mm detectable at ≥2 teeth (Tonetti et al., 2018)\n* Not having received subgingival instrumentation within the previous 12 months\n\nExclusion Criteria:\n\n* Medical history that includes serious medical conditions or transmittable diseases (e.g. serious cardiovascular disease, organ transplant, renal failure, AIDS, viral etc.).\n* Antibiotic, anti-inflammatory or anticoagulant therapy during the month preceding the baseline exam.\n* In treatment with drugs that induce gingival overgrowth\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures\n* History of alcohol or drug abuse.\n* Self-reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy and nursing, which can affect interpretation of study results).\n* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial.",{"count":196,"type":20},52,"This is a prospective cohort study that aims to describe the difference in terms of percentage of closed pockets (PPD \\\u003C5 mm and no BOP) when performing the periodontal re-evaluation at 3-4, 6-8 and 12 months.\n\nFifty-two, ≥18-year old, otherwise healthy, periodontitis patients will be recruited at Centro di Odontoiatria, Università di Parma.",[57,29],"2025-04-16",{"date":201,"type":35},"2025-04-17",{"date":203,"type":35},"2021-06-01",{"date":205,"type":20},"2026-12-31",{"name":207,"class":42},"University of Parma",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":224,"leadSponsor":226,"locationsCount":97},"100525535","modified-widman-flap-vs-fibre-retention-osseous-resective-surgery-100525535","NCT06123000","Modified Widman Flap vs Fibre Retention Osseous Resective Surgery","Modified Widman Flap (MWF) vs Fibre Retention Osseous Resective Surgery (FibReORS): A Randomized, Controlled, Clinical Trial.","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Patients affected by periodontitis;\n* No systemic disease or pregnancy;\n* No systemic antibiotic therapy in 6 months preceding the enrollment;\n* Smoking ≤ 20 cigarettes\u002Fday;\n* Full-mouth plaque score (FMPS) and full- mouth bleeding score (FMBS) ≤ 15%;\n* Residual periodontal pocket ≥5 mm with bleeding on probing at posterior natural teeth;\n* Experimental pocket associated with a detectable infrabony defect ≤ 3mm at x-ray;\n* No history of periodontal surgery at the experimental site.\n\nExclusion Criteria:\n\n* Undetectable cemento-enamel junction (CEJ) at experimental teeth;\n* Severe furcation involvement (class II and III);\n* Abutment for prosthetic rehabilitation;\n* Periodontal Pockets associated with infrabony defect \\>3 mm;\n* Horizontal bone loss higher than 1\u002F3 of the root length at experimental teeth;\n* Severe tooth mobility at baseline (class 2 or 3).",{"count":216,"type":20},36,[23],"The treatment of periodontitis should be carried out in an incremental manner, first by achieving adequate patient's oral hygiene practices and risk factor control during the first step of therapy and then, during the second step of therapy, by professional elimination (reduction) of supra and subgingival biofilm and calculus.\n\nIf the endpoints of therapy (no periodontal pockets \\>4 mm with bleeding on probing, BoP, or deep pockets ≥5 mm) have not been achieved, the third step of therapy should be implemented.\n\nIn fact, residual pockets following step 1 and 2 of periodontal treatment are associated with increased risk of periodontal disease progression in the long-term as reported by Claffey \\& Egelberg in1995. Residual probing depth (PPD) ≥5 mm after active therapy is a risk factor for disease progression and tooth loss during supportive periodontal therapy (SPT), suggesting that additional treatment of residual pockets is strongly recommended.\n\nThe third step of treatment includes the following interventions: repeated subgingival instrumentation, access flap periodontal surgery, resective periodontal surgery, regenerative periodontal surgery.\n\nIn case of residual pockets associated with shallow-moderate infrabony defects at posterior teeth, where both regenerative therapy and non-surgical re-instrumentation are usually not indicated, access flap procedures (i.e., the Modified Widman Flap, MWF) and the Osseous Resective Surgery (ORS) are considered two of the most viable options.\n\nThe value of these surgical techniques has been tested over the years by different clinical trials, and the choice of a surgical approach still relies mainly on the decision-making process of the surgeon, since the long-term outcomes of the different periodontal surgical procedures are similar, as highlighted by a recent systematic review.\n\nNevertheless, one the main criticism that have been moved against ORS, lies on the fact that the side effects (i.e., gingival recessions) seem to be more severe for ORS surgery, when compared with MWF.\n\nIn the early 2000s, Carnevale proposed the Fibre Retention Osseous Resective Surgery (FibReORS), an approach that leads to a more conservative bone resection to eliminate infrabony defects and establish a positive bony architecture than the conventional ORS. Indeed, this one, based on the histological findings by Gargiulo et al. (1961), uses the level of the connective tissue attachment - rather than the bottom of the osseous defect - as the reference to apply the principles of ORS.\n\nTwo randomized clinical trials demonstrated that FibReORS is similarly effective as ORS for PPD reduction with less final gingival recessions (REC), clinical attachment loss (CAL) patient morbidity.\n\nNevertheless, no studies have ever directly compared FibreORS with MWF. Therefore, the aim of this randomized clinical trial (RCT) is to compare the efficacy of FibReORS versus MWF in the treatment of periodontal pockets associated with infrabony defects ≤3 mm at posterior natural teeth.\n\nObjectives\n\nThe experimental hypothesis is:\n\nFibReORS is superior to MWF in achieving PPD closure (PPD \\\u003C4 mm without BoP) at posterior teeth associated with shallow-moderate infrabony defects.",[57,29,30],"2025-04-07",{"date":222,"type":35},"2025-04-10",{"date":37,"type":35},{"date":225,"type":20},"2026-10-21",{"name":227,"class":42},"University of Florence",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":97},"100548988","three-types-of-papilla-incision-in-periodontal-surgery-100548988","NCT06428149","Three Types of Papilla Incision in Periodontal Surgery","Wound Healing After Different Types of Papilla Incision in Periodontal Reconstruction Surgery. a Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients diagnosed with periodontal disease.\n* Active residual pockets associated with intraosseous defects that did not resolve with non-surgical treatment after 1 year of maintenance.\n* Intraosseous lesions with probing depth greater than 5 mm or extension of the radiographic defect greater than 4 mm.\n* Plaque index and bleeding index less than 30%.\n\nExclusion Criteria:\n\n* Systemic disease that contraindicates periodontal surgery.\n* Pregnant women.\n* Third molars or teeth with incorrect endodontic or restorative treatment.","80 Years",{"count":237,"type":20},30,[23],"Three types of papilla incision in periodontal reconstruction techniques will be compared.",[57,26,29],"2025-03-24",{"date":243,"type":35},"2025-03-28",{"date":245,"type":35},"2023-06-01",{"date":247,"type":20},"2026-12-01",{"name":96,"class":42},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":16,"minAge":257,"maxAge":150,"enrollmentInfo":258,"targetDuration":4,"studyType":21,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":4},"100585296","the-efficacy-of-salvia-officinalis-gel-in-the-treatment-of-periodontitis-clinical-trial-100585296","NCT06900517","The Efficacy of Salvia Officinalis Gel in the Treatment of Periodontitis CLINICAL TRIAL","The Efficacy of Salvia Officinalis Gel in the Treatment of Periodontitis by Monitoring Gingival Crevicular Fluid Volume and Interleukin 17 Concentration","clinical","Inclusion Criteria:\n\n* patients diagnosed with periodontitis had at least 20 natural teeth, with probing pocket depth (PPD) ≥ 5 mm and attachment loss ≥ 4 mm\n\nExclusion Criteria:\n\n* Exclusion criteria were pregnancy, lactation, smoking, and any systemic disease that might affect periodontal disease progression or require antibiotic usage. Likewise, patients who had received anti-inflammatory medications or antibiotics in the preceding three months were excluded.","25 Years",{"count":259,"type":20},23,[23],"From each participant, two sites of periodontal pockets ( ≥ 5 mm ) were selected and randomly allocated to either the test site (treated with scaling and RSD with S. officinalis gel) or the control site (treated with scaling and RSD alone).",[29],"2025-03-21",{"date":243,"type":35},{"date":266,"type":20},"2025-05-01",{"date":268,"type":20},"2025-11-01",{"name":270,"class":42},"University of Baghdad",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":149,"sex":16,"minAge":278,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":97},"100554951","phase-1-evaluation-of-2bromelain-gel-with-02chx-gel-as-subgingival-ldd-following-srp-in-stage-iiiii-and-grade-b-periodontitis--a-rct-100554951","NCT06505759","Evaluation of 2%Bromelain Gel With 0.2%CHX Gel as Subgingival LDD Following SRP in Stage II\u002FIII and Grade B Periodontitis -A RCT","Evaluation of 2%Bromelain Gel With 0.2%Chlorhexidine Gel as Subgingival Local Drug Delivery Following Scaling and Root Planing in Stage II\u002FIII and Grade B Periodontitis -Randomized Control Clinical Trail","Inclusion Criteria:\n\n* Patient with have chronic periodontitis in the age group between 30-50 years.\n* Patients having ≥20 teeth.\n\n  -.Patients with radiographic evidence of bone loss in atleast two teeth.\n* Patients who are systematically healthy.\n* Patients with localized pockets with probing depth of ≤ 5mm.\n* Patients who are cooperative and able to attend the hospital for regular follow-up.\n\nExclusion Criteria:\n\n* Patients who have received any surgical or nonsurgical therapy during past 6months\n* Pregnant or lactating females.\n* Use of systemic antibiotics in the past 6 months.\n* Patient who are not willing to give a written informed consent","30 Years","50 Years",{"count":216,"type":20},[282],"PHASE1","The current study is a prospective randomised study Evaluation of 2%Bromelain Gel With 0.2%Chlorhexidine Gel as Subgingival Local Drug Delivery Following Scaling and Root Planing in Stage II\u002FIII and Grade B Periodontitis",[29],"2025-01-09",{"date":287,"type":35},"2025-01-13",{"date":289,"type":35},"2024-07-01",{"date":291,"type":20},"2025-07",{"name":293,"class":42},"Krishnadevaraya College of Dental Sciences & Hospital",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":149,"sex":16,"minAge":17,"maxAge":235,"enrollmentInfo":301,"targetDuration":4,"studyType":21,"phases":303,"briefSummary":304,"conditions":305,"keywords":306,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":97},"100564059","effectiveness-of-srp-lipo-curcumin-gel-for-the-treatment-of-stage-iii-periodontitis-100564059","NCT06624241","Effectiveness of SRP+ Lipo-curcumin Gel for the Treatment of Stage III Periodontitis.","Clinical Evaluation of Lipo-Curcumin Gel in Association with SRP for the Treatment of Stage III Periodontitis: a Randomized and Controlled Clinical Trial.","Inclusion Criteria:\n\n* Patients with a diagnosis of periodontitis stage III (grades A to C)\n* on-smokers or former smokers who quit at least 1 year ago, and had not received any periodontal treatment in the 3 months prior to recruitment\n* FMPS \\\u003C 20% at baseline\n* Furcation not involved\n* Not Pregnant or Lactating\n* Signed informed consent\n\nExclusion Criteria:\n\n* Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C\\>7%, rheumatoid arthritis or any form of immunosuppression\n* Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment\n* Chronic intake of NSAIDs or steroids, currently",{"count":302,"type":20},40,[23],"The aim of the present study is to clinically and radiographically compare the effectivness of Scaling and Root Plannig (SRP) in association with lipo-curcumin gel (LC) respect SRP+ lipo-gel (L), SRP+ discharged (D) gel and SRP alone.\n\nThis study will be designed as a randomized clinical trial of 12-month duration. A total of 40 patients will be recruited and randomly equally distributed into 4 groups: an experimental group treated with SRP + LC, a first control group treated with SRP + L, a second control group treated with SRP+D and a third control group SRP alone.\n\nEach defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following SRP, experimental and control sites will be randomly chosen. The test sites will be t filled with a Lipo-Curcumin gel and sealed with cyanoacrylate. In the first control group the defects will be be filled with a Lipo gel and sealed with cyanoacrylate. In the second control sites he pocket defect will be filled with a discharged gel and sealed with cyanoacrylate, in the third control group SRP alone will be performed.\n\nPre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing.",[26,29,30],[307,308,309,57],"Curcumin","SRP","Liposome","2024-09-30",{"date":312,"type":35},"2024-10-02",{"date":314,"type":35},"2024-06-12",{"date":316,"type":20},"2025-09",{"name":318,"class":42},"G. d'Annunzio University",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":149,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":21,"phases":328,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":4},"100559904","phase-2-evaluation-of-iprf-with-vitd-as-an-adjunct-to-non-surgical-therapy-in-the-treatment-of-stage-iii-periodontitis-100559904","NCT06570200","Evaluation of iPRF With Vit.D As an Adjunct to Non-Surgical Therapy in the Treatment of Stage III Periodontitis","Evaluation of Injectable PRF With Vitamin D As an Adjunct to Non-Surgical Therapy in the Treatment of Stage III Periodontitis. A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Patients with healthy systemic condition.\n2. Adult patients ˃ 18 years old.\n3. Patients with Stage III periodontitis.\n4. Patients accept 3-month follow-up period (cooperative patients).\n5. Patients provide an informed consent.\n\nExclusion Criteria:\n\n1. Presence of prosthetic crowns.\n2. Extensive interproximal restorations.\n3. Periodontal therapy within the last 12 months.\n4. Having undergone surgical periodontal therapy or undergoing orthodontic treatment.\n5. Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis.\n6. The use of antibiotics or anti-inflammatory drugs 3-month prior to the procedure and till the end of 6-month of follow-up.\n7. Smokers.\n8. Pregnant females.",{"count":327,"type":20},45,[329],"PHASE2","a clinical trial will be made to investigate the effect of locally applied injectable prf (iPRF) plus vitamin D on the periodontal pockets in stage III periodontitis patients",[29],[333,334,335,336],"iPRF","vitamin D","Cholecalciferol","periodontal pocket","2024-08-22",{"date":339,"type":35},"2024-08-26",{"date":341,"type":20},"2024-10",{"date":343,"type":20},"2026-02",{"name":345,"class":42},"Cairo University",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":149,"sex":16,"minAge":353,"maxAge":235,"enrollmentInfo":354,"targetDuration":4,"studyType":21,"phases":356,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":97},"100553791","evaluation-of-nonsurgical-treatment-of-deep-periodontal-pockets-7-10mm-using-airflow-prophylaxis-master-device-with-erythritol-powder-vs-conventional-instrumentation-100553791","NCT06490679","Evaluation Of Nonsurgical Treatment Of Deep Periodontal Pockets (7-10mm) Using AIRFLOW® Prophylaxis Master Device With Erythritol Powder vs Conventional Instrumentation","Evaluation Of Nonsurgical Treatment Of Deep Periodontal Pockets (7-10mm) Using AIRFLOW® Prophylaxis Master Device With Erythritol Powder vs Conventional Instrumentation: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Systemically healthy patients.\n* Patients with an age range between 16 to 80 years.\n* Patients have a minimum of 20 teeth.\n* Periodontitis patients with at least one residual pocket with a probing depth ranging from 7 to 10 mm.\n* Cooperative patients able and willing to come for follow up appointments.\n\nExclusion Criteria:\n\n* Pregnant and lactation females.\n* Patients reporting systemic conditions (eg: diabetes).\n* Patients with severe or unstable upper respiratory tract infections, chronic bronchitis\u002Fasthma.\n* Patients with severe inflammation and\u002For osteonecrosis.","16 Years",{"count":355,"type":20},46,[23],"Periodontitis is a chronic condition associated with the inflammatory destruction of the periodontal tissues ultimately leading to tooth loss. Clinically, it is identified by key features such as clinical attachment loss (CAL), bleeding upon probing (BOP), and an increase in probing pocket depth (PPD), and\u002For gingival recession. Periodontitis is mediated by polymicrobial dysbiosis with keystone pathogens affecting the virulence of the entire biofilm community. The removal of this biofilm and its retention factors is the ultimate goal of clinical treatment and oral measures applied. The elimination of the biofilm has traditionally been achieved with the use of either hand instruments or power driven devices. Promoting periodontal health or diminishing bacterial presence and calculus buildup on teeth can be accomplished with the same efficacy whether using manual scalers and curettes or ultrasonic scaling instruments. Both hand and ultrasonic instruments are characterized by being time- consuming and requiring technical skill, often causing patient discomfort and post-treatment pain, including hypersensitivity resulting from the loss of hard tissue when scaling the tooth surface. Ultrasonic instruments tend to leave a rougher surface behind compared to hand instruments. While effective the current techniques all have their disadvantages. The aim of this study is to evaluate changes in probing depth clinically, Bleeding on probing, Clinical attachment level, Plaque index, Calculus index, Patient pain\u002Fdiscomfort, Patient satisfaction, Cost effectiveness, Treatment time and Number of pockets closed after using AIRFLOW® Prophylaxis Master device with erythritol powder.",[29,57,359,360],"Gingival Diseases","Gingival Bleeding",[362,363],"Air Abrasive","Erythritol","2024-08-07",{"date":366,"type":35},"2024-08-09",{"date":368,"type":35},"2024-03-01",{"date":370,"type":20},"2026-01-01",{"name":345,"class":42},{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":149,"sex":16,"minAge":278,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":21,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":4},"100556295","comparing-photodisinfection-of-chitosan-np-enriched-icg-over-icg-as-adjunct-to-ofd-rct-100556295","NCT06523244","Comparing Photodisinfection of Chitosan NP Enriched ICG Over ICG as Adjunct to OFD: RCT","Comparison of Photo Disinfection With Chitosan Nanoparticles Enriched ICG Over ICG as an Adjunct to Open Flap Debridement in Stage II\u002FIII Grade B\u002FC Periodontitis. RCT","Inclusion criteria:\n\n* Systemically healthy subjects\n* Age group 30-55yrs.\n* Diagnosed with Stages II\u002FIII grade B\u002FC periodontitis.\n* Presenting with persistent pocket depth ≥5mm after initial non-surgical therapy.\n* Optimal plaque control\n* Good compliance\n\nExclusion criteria:\n\n* Subjects on antibiotic therapy within last six months of enrollment\n* Previous history of periodontal surgery\n* Allergy to drugs and materials used in this study\n* Pregnant woman\n* Subjects with deleterious habits like smoking, tobacco chewing.","55 Years",{"count":19,"type":20},[23],"The current study is a prospective randomised study-Comparison of photodisinfection with chitosan nanoparticles enriched indocyanine green over indocyanine green as an adjunct to open flap debridement in the management of stage II\u002FIII grade B\u002FC periodontitis.",[29],"2024-07-26",{"date":386,"type":35},"2024-07-29",{"date":388,"type":20},"2024-07",{"date":390,"type":20},"2025-08",{"name":293,"class":42}]